Related Experiment Video
Updated: Oct 2, 2025
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
Lipid-Based Nanocarriers in Renal RNA Therapy
Chi-Ting Su1,2,3, Daniel H W See1, Jenq-Wen Huang3
1Department of Medicine, National Taiwan University Cancer Centre, Taipei 10672, Taiwan.
Insights
Chronic kidney disease (CKD) is a major health concern. RNA therapy using microRNAs or short interfering RNAs with lipid nanocarriers offers a promising new treatment for kidney diseases.
Area of Science:
- Nephrology
- Molecular Biology
- Biotechnology
Background:
- Chronic kidney disease (CKD) is a significant global health issue, ranking as the 12th leading cause of death worldwide.
- Multiple factors contribute to kidney disease pathogenesis, and microRNAs (miRNAs) have been implicated in various renal conditions.
- Dysregulated miRNAs present therapeutic potential, especially given the kidney's rapid uptake of interference RNA, making it suitable for RNA therapy.
Purpose of the Study:
- To explore the potential of RNA therapy, specifically using microRNAs (miRNAs) or short interfering RNAs (siRNAs), for managing kidney diseases.
- To highlight the advantages of lipid-based nanocarriers in enhancing the delivery and efficacy of RNA-related drugs for renal applications.
- To address the unmet need for effective treatments for certain renal diseases.
Main Methods:
- Investigating the role of microRNAs (miRNAs) and their dysregulation in kidney disease.
- Evaluating the feasibility of using interference RNA (iRNA) for therapeutic interventions in the kidney.
- Assessing the advancements in RNA therapy combined with lipid-based nanocarriers for drug delivery.
Main Results:
- MicroRNA (miRNA) dysregulation is linked to several kidney diseases, indicating potential therapeutic targets.
- The kidney's capacity for rapid uptake of interference RNA makes it a viable target for RNA-based treatments.
- Advances in RNA therapy and lipid-based nanocarriers have improved the efficiency and effectiveness of RNA drugs for renal disease.
Conclusions:
- RNA therapy, particularly using miRNAs or siRNAs delivered via lipid-based nanocarriers, represents a promising and adaptable treatment strategy for renal diseases.
- This approach offers a low-risk, viable option for conditions lacking effective treatments.
- Further development and clinical trials are needed, as few RNA-based drugs for renal parenchymal disease are currently available.
Abstract:
Kidney disease is a multifactorial problem, with a growing prevalence and an increasing global burden. With the latest worldwide data suggesting that chronic kidney disease (CKD) is the 12th leading cause of death, it is no surprise that CKD remains a public health problem that requires urgent attention. Multiple factors contribute to kidney disease, each with its own pathophysiology and pathogenesis. Furthermore, microRNAs (miRNAs) have been linked to several types of kidney diseases. As dysregulation of miRNAs is often seen in some diseases, there is potential in the exploitation of this for therapeutic applications. In addition, uptake of interference RNA has been shown to be rapid in kidneys making them a good candidate for RNA therapy. The latest advancements in RNA therapy and lipid-based nanocarriers have enhanced the effectiveness and efficiency of RNA-related drugs, thereby making RNA therapy a viable treatment option for renal disease. This is especially useful for renal diseases, for which a suitable treatment is not yet available. Moreover, the high adaptability of RNA therapy combined with the low risk of lipid-based nanocarriers make for an attractive treatment choice. Currently, there are only a small number of RNA-based drugs related to renal parenchymal disease, most of which are in different stages of clinical trials. We propose the use of miRNAs or short interfering RNAs coupled with a lipid-based nanocarrier as a delivery vehicle for managing renal disease.
More Related Videos
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...